Sign in
Taking peopleNo phase

RDN for CKD and Uncontrolled Hypertension Trial

Key facts

Who runs it
Beijing Anzhen Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
248 people, planned
Started
8 Dec 2025
Expected to end
30 Apr 2028
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Radiofrequency Renal Denervation System
  • Parallel control
Record updated
18 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Male or female, aged 18 to 65 years, inclusive, at the time of consent
  • Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg
  • Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²
  • The presence or absence of accessory renal arteries is acceptable
  • The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form

Who cannot take part

  • Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis
  • Prior renal artery intervention or prior renal denervation
  • Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months
  • History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker
  • Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS
  • Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements
  • Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted)
  • Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.)
  • Allergic to contrast agents
  • Type 1 diabetes mellitus
  • Primary pulmonary arterial hypertension
  • History of bleeding diathesis and haematological disorders or coagulopathy
  • History of thromboembolic event within 6 months
  • History of stroke or transient ischemic attack (TIA) within 6 months
  • Severe peripheral arterial disease or unstable abdominal aortic aneurysm
  • Severe valvular heart disease or anticipated need for surgical valve replacement during the study period
  • NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months
  • Acute or severe systemic infection
  • Other conditions deemed unsuitable for participation by the investigator
  • Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours)
  • Pregnant or breastfeeding, or planning pregnancy during the study
  • Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm)
  • Orthostatic hypotension
  • Severe hepatic dysfunction

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hypertension or CKD - chronic kidney disease

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

The 2 groups in the trial

  • Renal Denervation (RDN)Treatment being tested

    Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

    Treatment: Radiofrequency Renal Denervation System

  • Parallel control with sham operationSham treatment, for comparison

    Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

    Treatment: Parallel control

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial
Criteria questions
Built from NCT07945795, who can take part
Record updated
18 November 2026